US Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedView

US Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedView

  • November 2016 •
  • 58 pages •
  • Report ID: 4353015 •
  • Format: PDF
Description
Diabetes mellitus is a multifaceted disease that yields various approaches in terms of diagnosis, treatment and drug delivery. Products for maintenance and treatment of diabetes can be of high volume and low cost or of relatively low volume and high cost. The U.S. diabetes monitoring, treatment and drug delivery market increased in value in 2016 and growth is expected to persist over the forecast period. Growth will be driven by the increasing prevalence of diabetes in the U.S. and technological advancements made in certain segments, particularly insulin pumps and continuous glucose monitoring (CGM). Limitations to market growth include pricing pressure due to recent CMS reimbursement changes and the negative impact on the overall blood glucose monitoring market. The recent influx of low-price competitors in the blood glucose test strip segment has also placed downward pressure on prices and resulted in market value contractions despite the growing volume and increasing number of diabetics testing their blood glucose levels.

Abstract
The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are “ultra-long-acting” and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an “ultra-rapid-acting” insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.
Scope:2013-2023
Companies
Sanofi
Novo Nordisk
Eli Lilly
Medtronic
Johnson & Johnson
Becton Dickinson
Abbott
Roche
DexCom
Ascensia
Insulet
Trividia Health
Tandem
Nova Biomedical
Valeritas